2019 Future of Reflex sympathetic dystrophy syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 2F25531E5B1EN
VPAResearch

Abstracts

The global demand for Reflex sympathetic dystrophy syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Reflex sympathetic dystrophy syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Reflex sympathetic dystrophy syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.

Reflex sympathetic dystrophy syndrome Report Description-

The 2019 pipeline study on Reflex sympathetic dystrophy syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Reflex sympathetic dystrophy syndrome pipeline compounds.

The Reflex sympathetic dystrophy syndrome pipeline guide presents information on all active drugs currently being developed for Reflex sympathetic dystrophy syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Reflex sympathetic dystrophy syndrome pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Reflex sympathetic dystrophy syndrome drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Reflex sympathetic dystrophy syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Reflex sympathetic dystrophy syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Reflex sympathetic dystrophy syndrome pipeline report includes-

• An overview of Reflex sympathetic dystrophy syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Reflex sympathetic dystrophy syndrome pipeline
• Company wise list of Reflex sympathetic dystrophy syndrome pipeline
• Mechanism of Action wise Reflex sympathetic dystrophy syndrome pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Reflex sympathetic dystrophy syndrome pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Reflex sympathetic dystrophy syndrome pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Reflex sympathetic dystrophy syndrome pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Reflex sympathetic dystrophy syndrome Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Reflex sympathetic dystrophy syndrome pipeline, H1- 2019
3.5 Mechanism of Action wise Reflex sympathetic dystrophy syndrome Pipeline Candidates

4 ABIOGEN PHARMA SPA COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

4.1 Abiogen Pharma SpA Business Profile
4.2 Abiogen Pharma SpA Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BIOHAVEN PHARMACEUTICALS COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

5.1 Biohaven Pharmaceuticals Business Profile
5.2 Biohaven Pharmaceuticals Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 GRUNENTHAL GMBH COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

6.1 Grunenthal GmbH Business Profile
6.2 Grunenthal GmbH Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 NEUROTHERPIA INC COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

7.1 NeuroTherpia Inc Business Profile
7.2 NeuroTherpia Inc Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 PIRAMAL ENTERPRISES LTD COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

8.1 Piramal Enterprises Ltd Business Profile
8.2 Piramal Enterprises Ltd Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 TETRA BIO-PHARMA INC COMPLEX REGIONAL PAIN SYNDROME (CPRS)/REFLEX SYMPATHETIC DYSTROPHY SYNDROME PIPELINE DETAILS

9.1 Tetra Bio-Pharma Inc Business Profile
9.2 Tetra Bio-Pharma Inc Complex Regional Pain Syndrome (CPRS)/reflex sympathetic dystrophy syndrome Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. LATEST REFLEX SYMPATHETIC DYSTROPHY SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019

11. APPENDIX

11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information